Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07339488 | Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma | PHASE2 | ACTIVE NOT_RECRUITING | 43 | — | — | Nov 1, 2025 | Nov 1, 2028 | Jan 14, 2026 | 1 | China |
The proportion of patients who, following conversion therapy, exhibit no residual invasive cancer cells in either the primary tumor site or regional lymph nodes upon pathological evaluation of surgical resection specimens, expressed as a percentage of the total treated population.
| Arm | Type | Description |
|---|---|---|
| ILDR plus immunochemotherapy plus surgery | EXPERIMENTAL | 1Gy/1F ILDR + albumin-bound paclitaxel (3 cycles of 260 mg/m² on day 1), cisplatin (3 cycles of 75 mg/m² on day 1), and tislelizumab (3 cycles of 200 mg on day 1) + surgery |
| Name | Type | Description |
|---|---|---|
| Intestinal Low Dose Radiotherapy-1Gy | RADIATION | 1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum. |
| PD-1/PD-L1 inhibitors | DRUG | 3 cycles of tislelizumab（200 mg D1 q3w） |
| Chemotherapy | DRUG | 3 cycles of albumin-bound paclitaxel（260 mg/m2 D1 q3w）+ cisplatin（75 mg/m2 D1 q3w） |
| Surgery | PROCEDURE | McKeown esophagectomy or laparoscopic-assisted McKeown esophagectomy is recommended, with either two-and-a-half-field lymphadenectomy or three-field lymph node dissection. |
Inclusion Criteria: 1. Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance. 2. Age ≥18 years and ≤75 years; both sexes are eligible. 3. ECOG performance status score of 0-1. 4. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) p...